Skip to Content
Merck
CN
All Photos(1)

Key Documents

Safety Information

55465-U

Supelco

Discovery® Glycan SPE Tube

bed wt. 50 mg, volume 1 mL, pk of 108

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
41115712
NACRES:
NB.21

material

PE frit
polypropylene

composition

bed wt., 50 mg

packaging

pk of 108

technique(s)

solid phase extraction (SPE): suitable

volume

1 mL

impurities

<5% Water content

matrix

polyamide resin base material

matrix active group

amide, poly- phase

particle size

50-160 μm

pH range

4.5-7.5(surface pH)

bulk density

0.2‑0.3 g/mL

separation technique

reversed phase

Looking for similar products? Visit Product Comparison Guide

General description

Retention Mechanism: Reversed-phase
Sample Matrix Compatibility: Aqueous or methanolic solutions

  • Polyamide Resin: Particle Size: 50-160 μm, Surf pH: 4.5-7.5, Density: 0.2-0.3 cm3/g, Water Content: < 5 %
  • Useful for extracting gylcans from aqueous solutions.
  • Used to adsorb polar compounds (-OH groups, esp. phenolic compounds) from aqueous or methanolic solutions under the reversed-phase mechanism through strong hydrogen bonding between compound hydroxyl groups and amide groups of the resin
  • Also may be used for the extraction of tannins, chlorophyll, humic acid, pharmacologically active terpenoids, flavanoids, gallic acid, catechol A, protocatechuic acid, phloroglucinol, aromatic carboxylic acids, and nitroaromatic compounds
  • Irreversibly retains quinones.

Legal Information

Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

新产品

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
14652201
13726901
13043701
12324401
11387801

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Hsin-Yuan Chen et al.
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 49(5), 1970-1986 (2018-09-21)
Uterine leiomyomas (ULs) are benign uterine tumors, and the most notable pathophysiologic feature of ULs is excessive accumulation of extracellular matrix (ECM). Fucoidan is a polysaccharide extracted from brown seaweeds that has a wide range of pharmacological properties, including anti-fibrotic
Wei Liu et al.
Glycobiology, 28(6), 363-373 (2018-03-22)
O-linked N-acetylglucosamine (O-GlcNAcylation) is an important post-translational modification on serine or threonine of proteins, mainly observed in nucleus or cytoplasm. O-GlcNAcylation regulates many cell processes, including transcription, cell cycle, neural development and nascent polypeptide chains stabilization. However, the facile identification
Weston B Struwe et al.
Cell reports, 24(8), 1958-1966 (2018-08-23)
Many broadly neutralizing antibodies (bnAbs) against HIV-1 recognize and/or penetrate the glycan shield on native, virion-associated envelope glycoprotein (Env) spikes. The same bnAbs also bind to recombinant, soluble trimeric immunogens based on the SOSIP design. While SOSIP trimers are close
Qingxin Cui et al.
Frontiers in pharmacology, 9, 948-948 (2018-09-07)
Purpose: Understanding the distribution and interaction of the Traditional Chinese Medicines (TCMs) is an integral source of herbal drug discovery. An optimized radio-labeled method was explored that could conduct in situ biodistribution studies in animals. We evaluated the feasibility of
Tongqing Zhou et al.
Immunity, 48(3), 500-513 (2018-03-20)
Virtually the entire surface of the HIV-1-envelope trimer is recognized by neutralizing antibodies, except for a highly glycosylated region at the center of the "silent face" on the gp120 subunit. From an HIV-1-infected donor, #74, we identified antibody VRC-PG05, which
View All Related Papers

Articles

Released N-Glycan Analysis of a Therapeutic Antibody Using BIOshell™ Glycan Column

This application note describes the released N-Glycan analysis of a monoclonal antibody, cetuximab, labeled with procainamide, using a BIOshell™ Glycan HPLC column.

Rapid Glycan Prep & Analysis by LC-MS Workflow

PNGase Fast denaturing buffer and enzyme provide results similar to a conventional 20-hour protocol, reducing workflow time to about 1 hour.

Solid Phase Extraction: Reversed-Phase Methodology

Reversed-phase interaction will retain most molecules with hydrophobic character; it is very useful for extracting analytes that are very diverse in structure within the same sample.

Protocols

Released N-Linked Glycan Analysis Workflow of Adalimumab

A step-by-step protocol for released N-linked glycan analysis of the monoclonal antibody adalimumab, based on UHPLC-FLR-MS and procainamide labeling.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service